FDA, NIH Devise Regulatory Research Agenda, Look For Financing
This article was originally published in The Gray Sheet
Executive Summary
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translational Science Awards program.
You may also be interested in...
NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
New NIH Center May Offer More Opportunity For FDA Collaboration
FDA hopes the National Institute of Health’s proposed new National Center for Advancing Translational Science will trigger more collaboration between the two agencies through shared grant making, FDA Commissioner Margaret Hamburg said last week.
NIH Translational Research Consortium Mulls How Best To Leverage Agency's Stake In Industry, Academia, Government Relationships
"We all have different carrots and different challenges, but we also have a great deal in common, including the goal to provide improved treatments and preventions for the public," says NCRR Director Alving.